NewAmsterdam Pharma Company NV has published a document detailing the safety and efficacy of obicetrapib in patients at high cardiovascular risk. The document includes information on a study involving 2530 adult participants with heterozygous familial hypercholesterolemia and/or atherosclerotic cardiovascular disease. Key findings include the placebo-adjusted reduction in LDL-C with obicetrapib, which was 32.6% at day 84 and 24.0% at day 365. The full document can be accessed through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。